Reprint
Advances and Novel Treatment Options in Metastatic Melanoma
Edited by
February 2022
528 pages
- ISBN978-3-0365-3304-9 (Hardback)
- ISBN978-3-0365-3303-2 (PDF)
This book is a reprint of the Special Issue Advances and Novel Treatment Options in Metastatic Melanoma that was published in
Biology & Life Sciences
Medicine & Pharmacology
Summary
The book presents several studies reporting advances on melanoma pathogenesis, diagnosis and therapy. It represents a milestone on the state of the art, updated at 2021, and also presents the current knowledge on the future developments in melanoma field.
Format
- Hardback
License
© 2022 by the authors; CC BY-NC-ND license
Keywords
melanoma; invasion; WNT5A; MARCKS; phosphorylation; MANS peptide; melanoma; nanoparticles; cell therapy; tumor microenvironment; melanoma; sex/gender; sex-hormones; immunity; microRNAs; immunotherapy; BRAF-mutant melanoma; BRAF inhibitor; mechanism of action; melanoma; targeted therapy; tumour microenvironment; plasmacytoid dendritic cells; melanoma; lactate dehydrogenase; TLR; interferon; CXCL10; TPC2; HIPPO; melanoma; SOCE; metastasis; melanoma; essential oils; angiogenesis; apoptosis; metastasis; uveal melanoma (UM); metastatic uveal melanoma (mUM); prognostication; adjuvant therapy; metastatic therapy; metastatic dormancy; liver-directed-therapies; immunotherapy; targeted-therapy; combined therapy; melanoma; protein tyrosine phosphatase; PTPs inhibitors; melanoma immune infiltrate; BRAF inhibitors; melanoma; metastasis; microenvironment; resistance; therapy; melanoma; targeted therapy; immunotherapy; tumor microenvironment; therapeutic resistance; nanoparticles; exosomes; extracellular vesicles; melanoma; therapy; diagnosis; prognosis; ctDNA; melanoma; liquid biopsy; prognosis; prediction; patient stratification; melanoma; BRAF; BRAF inhibitor; arthralgia; rheumatoid arthritis; carbonic anhydrase; hedgehog; cyclopamine; small molecules; acetazolamide; motility; metalloproteinases; FAK; cancer; mucosal melanoma; nivolumab; pembrolizumab; ipilimumab; radiotherapy; cholinergic system; acetylcholine; muscarinic receptors; nicotinic receptors; melanoma; cancer; melanoma metastasis; ShcD adaptor protein; amoeboid motility; Rac1; DOCK4; melanoma PDX; melanoma; target therapy; cancer stem cells; slow cycling phenotype; drug resistance; OXPHOS; lipid metabolism; melanoma; cancer associated fibroblast; tumor microenvironment; melanomagenesis; biomarkers; melanoma; checkpoint inhibitor; PD-1; target therapy; melanoma markers; cytokines; machine learning; Support Vector Machine; principal component analysis; BCL2L10; STAT3; melanoma; cytotoxicity; survival; ABT-737; Bcl-2 family; ML258; melanoma; HuR; MITF; metastases; siRNA; targeted therapy; nanoparticles; n/a